Get started
Author

S. Anyanwu

Observed names: S Anyanwu, S I Anyanwu, Stephanie Anyanwu
OpenAlex ID: A5061669463
A Phase 1b Study to Evaluate the Safety and Efficacy of Durvalumab in Combination With Tremelimumab or Danvatirsen in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
2020 · Vincent Ribrag, Seung Tae Lee, et al. · Clinical Lymphoma Myeloma & Leukemia · 30
Pos0220 Integrated Safety Profile of Upadacitinib With up to 4.5 Years of Exposure in Patients With Rheumatoid Arthritis
2021 · S.B. Cohen, R. Van Vollenhoven, et al. · Annals of the Rheumatic Diseases · 5
OP17 Upadacitinib Improves Endoscopic Outcomes in Patients with Moderate to Severely Active Crohn’s Disease Irrespective of Previous Failure to Respond to Biologics or Conventional Therapies
2023 · B G Feagan, S Horst, et al. · Journal of Crohn s and Colitis · 4
PDF
OP10 Efficacy and safety of upadacitinib in patients with moderately to severely active Crohn’s Disease: results from the U-ENDURE long-term extension
2024 · G D'Haens, E Louis, et al. · Journal of Crohn s and Colitis · 3
PDF
Pos0656 Relationship Between Changes in Lipid Levels and Improvement in Disease Activity Outcomes in Patients With Rheumatoid Arthritis Receiving Upadacitinib Treatment: Pooled Analysis of Data From Two Phase 3 Studies
2021 · C. Charles-Schoeman, J.T. Giles, et al. · Annals of the Rheumatic Diseases · 3
PDF
DOP40 Corticosteroid discontinuation and clinical outcomes in patients with moderately to severely active Crohn’s disease treated with upadacitinib
2023 · M C Dubinsky, G D’Haens, et al. · Journal of Crohn s and Colitis · 2
PDF
DOP47 Characterisation of endoscopic improvement in Crohn’s Disease with upadacitinib treatment
2024 · R Panaccione, G Y Melmed, et al. · Journal of Crohn s and Colitis · 1
PDF
Pos0222 Predictors of Response: Baseline Characteristics and Early Treatment Responses Associated With Achievement of Remission and Low Disease Activity Among Upadacitinib-treated Patients With Rheumatoid Arthritis
2021 · A. Kavanaugh, Z. Szekanecz, et al. · Annals of the Rheumatic Diseases · 1
PDF
P509 Upadacitinib improves symptomatic responses in patients with moderately to severely active Crohn’s disease
2024 · I Blumenstein, J Torres, et al. · Journal of Crohn s and Colitis
PDF
P1040 Comparative effectiveness of upadacitinib versus ustekinumab in patients with moderately to severely active Crohn’s disease: a matching-adjusted indirect comparison
2024 · C Ma, M C Dubinsky, et al. · Journal of Crohn s and Colitis
PDF
P506 Endoscopic and clinical outcomes of upadacitinib in patients with moderate to severe Crohn’s disease by baseline disease severity
2023 · B Siegmund, K Patel, et al. · Journal of Crohn s and Colitis
PDF
Pos0693 Impact of Upadacitinib Versus Abatacept on Individual Disease Outcomes in Patients With Rheumatoid Arthritis and Inadequate Responses to Biologic Dmards
2022 · R. Van Vollenhoven, A. Rubbert-Roth, et al. · Annals of the Rheumatic Diseases
PDF
Pos0541 Predictors of Remission in Rheumatoid Arthritis Patients Treated With Upadacitinib or Adalimumab in the Select-compare Phase 3 Study: Clinical Status at Week 12, but Not Standard Laboratory Measures, Provides the Best Current Predictor of Remission at Week 26
2022 · T. Sornasse, F. Cai, et al. · Annals of the Rheumatic Diseases
PDF
Profil de tolérance intégré d’upadacitinib chez des patients atteints de polyarthrite rhumatoïde après une durée d’exposition pouvant aller jusqu’à 4,5 ans
2021 · C. Richez, S.B. Cohen, et al. · Revue du Rhumatisme
Op0128 Integrated Laboratory Abnormality Profiles of Upadacitinib With up to 4.5 Years of Exposure in Patients With Rheumatoid Arthritis Treated in the Select Phase 3 Program
2021 · C. Charles-Schoeman, J.T. Giles, et al. · Annals of the Rheumatic Diseases
PDF
Hormonal Contraceptives Use and the Fear of Cervical Cancer as Its Affect the Nigerian Population Growth
2018 · IJ Inyang, M Udonkang, et al. · International Journal of Medical Laboratory Research
PDF
Works count: 16
Citation count: 49
H-index: 3
I10-index: 1
Year
Topic
Type